Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide

Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide

Saved in:

Bibliographic Details
Main Authors:	Rui Huang, Chunli Zhang, Xiaodong Mo, Huiying Rao, Rongman Jia
Format:	Article
Language:	English
Published:	Wolters Kluwer 2025-01-01
Series:	Chinese Medical Journal
Online Access:	http://journals.lww.com/10.1097/CM9.0000000000003417
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A New Hope for the Patients of Non‐Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use
by: Abdul Haseeb Hasan, et al.
Published: (2025-01-01)

Appendicitis After Initiation of Tirzepatide
by: Chan G, et al.
Published: (2025-01-01)

Effects of Metabolic Dysfunction–Associated Steatohepatitis in Alertness, Associative Learning, and Astrocyte Density
by: Sara G. Higarza, et al.
Published: (2025-01-01)

Tirzepatide in Sport: A Comprehensive Review of its Metabolic Impacts and Potential Applications for Athletes
by: Wiktor Biesiada, et al.
Published: (2025-01-01)

Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations
by: Alia Hadefi, et al.
Published: (2025-01-01)

Targeted Plasma Bile Acid Metabolomic Analysis in Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Hepatitis
by: Yuta Hirata, et al.
Published: (2024-12-01)

FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
by: Muhammad Mazhar Azam, et al.
Published: (2024-12-01)

Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction
by: Khanh Tran, et al.
Published: (2009-01-01)

A mutation in LXRα uncovers a role for cholesterol sensing in limiting metabolic dysfunction-associated steatohepatitis
by: Alexis T. Clark, et al.
Published: (2025-01-01)

PHARMACOTHERAPY IN PATIENTS WITH ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA IN THE ABSENCE OF RISK OF DISEASE PROGRESSION
by: A. A. Kamalov, et al.
Published: (2018-03-01)

Protective Role of Black Tea Extract against Nonalcoholic Steatohepatitis-Induced Skeletal Dysfunction
by: Subhra Karmakar, et al.
Published: (2011-01-01)

Pharmacotherapy of Posttraumatic Cognitive Impairments
by: David B. Arciniegas, et al.
Published: (2006-01-01)

Pharmacotherapy of Peptic Ulcer Disease
by: F Molina, et al.
Published: (1991-01-01)

Aberrant Hepatic Methionine Metabolism and Gene Methylation in the Pathogenesis and Treatment of Alcoholic Steatohepatitis
by: Charles H. Halsted, et al.
Published: (2012-01-01)

The Pharmacotherapy of Chronic Pain: A Review
by: Mary E Lynch, et al.
Published: (2006-01-01)

MORE ATTENTION TO QUALITY OF PHARMACOTHERAPY IN PSYCHIATRY
by: ERKKI ISOMETSÄ
Published: (2024-11-01)

CISD2-mediated mitochondrial dysfunction and iron redistribution contributes to ferroptosis in arsenic-induced nonalcoholic steatohepatitis
by: Jingyuan Zhang, et al.
Published: (2025-01-01)

Acyl-CoA Thioesterase 1 Contributes to Transition of Steatosis to Metabolic-Associated Steatohepatitis
by: Elisa Pasini, et al.
Published: (2024-01-01)

Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
by: Zijun Ma, et al.
Published: (2023-01-01)

Effects of celastrol on the heart and liver galaninergic system expression in a mouse model of Western-type diet-induced obesity and metabolic dysfunction-associated steatotic liver disease and steatohepatitis
by: Nikolina Canová, et al.
Published: (2025-02-01)

Pharmacotherapies for Obesity: Past, Current, and Future Therapies
by: Lisa L. Ioannides-Demos, et al.
Published: (2011-01-01)

Weight Considerations in Pharmacotherapy for Type 2 Diabetes
by: Vicky Cheng, et al.
Published: (2011-01-01)

Cerebral Cavernous Malformation: From Genetics to Pharmacotherapy
by: Zhuangzhuang Zhang, et al.
Published: (2025-01-01)

Nonalcoholic Steatohepatitis in Nondiabetic Obese Patients
by: Idilio Zamin, et al.
Published: (2002-01-01)

Recent Advances in Pharmacotherapy Development for Abdominal Aortic Aneurysm
by: Koichi Yoshimura, et al.
Published: (2012-01-01)

Editorial: Advances in the pharmacotherapy of chronic pelvic pain conditions
by: Elena Lucarini, et al.
Published: (2025-01-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Medical nutritional therapy during pharmacotherapy for obesity: expert insights
by: Matylda Kręgielska-Narożna, et al.
Published: (2024-12-01)

Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
by: S. Gitto, et al.
Published: (2015-01-01)

Ursodeoxycholic Acid and Atorvastatin in the Treatment of Nonalcoholic Steatohepatitis
by: Murat Kiyici, et al.
Published: (2003-01-01)

Expert Consensus on Tiered Detection of Newly Emerging and Outbreak Respiratory Infectious Pathogens (2024)
by: Chinese Hospital Association Clinical Microbiology Laboratory Specialized Committee
Published: (2025-01-01)

A Pharmacotherapy and ECT resistant OCD patient’s Cognitive Behavioral Therapy
by: Tacettin KURU, et al.
Published: (2013-11-01)

Review of Current First-Line Pharmacotherapy Strategies for Thyroid Eye Disease
by: Julia Ryniecka, et al.
Published: (2025-01-01)

Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review
by: Lei Lu, et al.
Published: (2018-01-01)

Artificial Intelligence in Identifying Patients With Undiagnosed Nonalcoholic Steatohepatitis
by: Onur Baser, et al.
Published: (2024-09-01)

Nonalcoholic Steatohepatitis: More Than Just Being Fat
by: Eldon A Shaffer
Published: (2002-01-01)

Inflammatory Regulation in Diabetes and Metabolic Dysfunction
by: Jixin Zhong, et al.
Published: (2017-01-01)

Insights from a cluster of tuberculosis outbreak in a psychiatric hospital—Shandong Province, 2024
by: Shulei Wang, et al.
Published: (2025-03-01)

Ethanol extract of Polygonatum cyrtonema Hua mitigates non-alcoholic steatohepatitis in mice
by: Dongliang Chen, et al.
Published: (2025-01-01)

A Pharmacotherapy and ECT resistant OCD patients Cognitive Behavioral Therapy
by: Tacettin KURU, et al.
Published: (2013-12-01)